Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    silenseed
Show Display Options
Rank Status Study
1 Not yet recruiting A Phase II Study of siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Ductal Adenocarcinoma;   Pancreatic Cancer
Interventions: Drug: siG12D LODER;   Drug: Gemcitabine or FOLFIRINOX
2 Completed Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas
Conditions: Pancreatic Ductal Adenocarcinoma;   Pancreatic Cancer
Intervention: Drug: siG12D LODER

Indicates status has not been verified in more than two years